MRSN - Mersana Therapeutics Inc
IEX Last Trade
1.57
0.050 3.185%
Share volume: 479,849
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.52
0.05
3.29%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 252.351 M | 314.850 M | 334.340 M | 296.195 M | 311.000 M | 262.904 M | 226.060 M | 198.373 M | |
| Current Assets | 237.079 M | 300.037 M | 319.219 M | 281.807 M | 297.087 M | 249.738 M | 214.057 M | 187.538 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 11.951 M | 9.911 M | 8.507 M | 7.888 M | 10.499 M | 8.752 M | 4.973 M | 4.392 M | |
| Short Term Investments | 11.951 M | 9.911 M | 8.507 M | 7.888 M | 10.499 M | 8.752 M | 4.973 M | 4.392 M | |
| Total Receivables | 0.000 | 0.000 | 30.000 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 225.128 M | 290.126 M | 280.712 M | 273.919 M | 286.588 M | 240.986 M | 209.084 M | 183.146 M | |
| Total Non-current Assets | 15.272 M | 14.813 M | 15.121 M | 14.388 M | 13.913 M | 13.166 M | 12.003 M | 10.835 M | |
| Property Plant Equipment | 2.854 M | 3.136 M | 3.985 M | 3.994 M | 4.266 M | 4.265 M | 3.831 M | 3.408 M | |
| Other Assets | 12.418 M | 11.677 M | 11.136 M | 10.394 M | 9.647 M | 8.901 M | 8.172 M | 7.427 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 252.351 M | 314.850 M | 334.340 M | 296.195 M | 311.000 M | 262.904 M | 226.060 M | 198.373 M | |
| Total liabilities | 118.317 M | 224.621 M | 242.283 M | 231.901 M | 221.200 M | 210.709 M | 189.156 M | 170.388 M | |
| Total current liabilities | 71.470 M | 88.794 M | 91.533 M | 83.402 M | 74.920 M | 67.933 M | 63.637 M | 53.406 M | |
| Accounts Payable | 8.158 M | 13.732 M | 13.951 M | 18.156 M | 16.918 M | 12.946 M | 7.319 M | 3.086 M | |
| Other liabilities | 12.012 M | 101.683 M | 117.246 M | 115.722 M | 114.273 M | 111.571 M | 97.222 M | 92.660 M | |
| Current long term debt | 2.592 M | 2.697 M | 2.798 M | 2.904 M | 3.025 M | 3.137 M | 5.335 M | 8.755 M | |
| Long term debt | 34.835 M | 34.144 M | 33.504 M | 32.777 M | 32.007 M | 31.205 M | 28.297 M | 24.322 M | |
| Other liabilities | 12.012 M | 101.683 M | 117.246 M | 115.722 M | 114.273 M | 111.571 M | 97.222 M | 92.660 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 134.034 M | 90.229 M | 92.057 M | 64.294 M | 89.800 M | 52.195 M | 36.904 M | 27.985 M | |
| Common stock | 95.757 M | 97.642 M | 101.290 M | 107.515 M | 115.608 M | 120.522 M | 120.807 M | 121.425 M | |
| Retained earnings | -549.956 M | -609.767 M | -654.691 M | -710.854 M | -765.161 M | -806.817 M | -826.361 M | -845.667 M |